This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?
by Ahan Chakraborty
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.
biotechnology biotechs medical pharmaceuticals
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
by Kinjel Shah
Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.
pharmaceuticals
JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?
by Kinjel Shah
JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.
pharmaceuticals
Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal
by Aparajita Dutta
Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.
etfs pharmaceuticals
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play
by Kinjel Shah
Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.
pharmaceuticals
MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?
by Kinjel Shah
Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.
pharmaceuticals
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron
by Zacks Equity Research
Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies.
biotechnology biotechs medical pharmaceuticals
Pharma ETF (XPH) Hits a New 52-Week High
by Sanghamitra Saha
Pharma ETF XPH hits a fresh 52-week high as healthcare shines amid AI bubble fears and slowing growth. Biotech M&A adds fuel -- can momentum hold?
etfs pharmaceuticals
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's
by Zacks Equity Research
Sandoz, Teva and Dr. Reddy's emerge as standouts as generic drugmakers lean on biosimilars, complex generics and tighter cost controls.
pharmaceuticals
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
by Ekta Bagri
Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.
biotechnology biotechs medical pharmaceuticals